Bryce worked with Eli Lilly & Co. for over 36 years and was a member of the Executive Committee and an Officer of the Company, In December 2011, he retired as Executive VP Eli Lilly and Co & President of Lilly Bio-Medicines.
Bryce held strategic and operational responsibility for the Lilly Bio-Medicines Business Unit comprising both the clinical development of late stage products across multiple therapeutic areas and regional sales and marketing operations for United States, Japan, the European Union, Canada, and Australia / New Zealand. He also was responsible for the Lilly Global Marketing organisation.
Prior to the above role he was Executive Vice President, Global Marketing and Sales encompassing all therapeutic areas and the operational responsibilities for the global pharmaceutical division.
Bryce has had extensive product development leadership roles overseeing post proof-of-concept global development teams for the entire Lilly late stage pipeline across all therapeutic categories. During his career, he also held multiple operational roles as President of Lilly Japan, Managing director of Australia/New Zealand and General Manager of a Joint Venture in South Korea.
Bryce contributed in leadership positions to the pharmaceutical industry associations internationally. Currently he is a member of the Deans Council for Indiana University School of Public Policy & Environmental Affairs, Indiana USA and a Board Director of Kazia Therapeutics Ltd. Bryce was born in New Zealand, where he gained his B.Sc. in biochemistry from Massey University. He currently resides in both Chicago and Sydney.
Rosanne has over 20 years experience in biomedical research, translational medicine, clinical research, regulatory affairs and drug development. She resides in Sydney.
She was a co-founder & Director of Immune System Therapeutics Ltd from 2001 to 2012 where she managed the intellectual property portfolio and was an author on the company's patents. She played a lead role in the isolation of the genes for the lead therapeutic antibody and was involved in taking the antibody from the laboratory through preclinical and clinical development.
She has experience in the field of immunology, haematology and molecular biology with particular experience in the development of biologic therapeutics. Rosanne heads the HaemaLogiX team in the development of the chimeric antigen receptor (CAR) program and the clinical development of the antibody pipeline.
Rosanne was awarded a PhD in antibody engineering from the University of Technology, Sydney. She has a Masters of Medical Science from the University of Natal Medical School and a BSc (Hons) in biochemistry from the University of Cape Town in South Africa. She is a graduate of the Australian Institute of Company Directors and is a member of the European Haematology Association, the American Society of Clinical Oncology and the International Myeloma Society.
Dimitra is a Certified Practicing Accountant (CPA) which she obtained after converting her Bachelor of Science Degree (UNSW) through an accounting bridging course from the University of Technology, Sydney.
As Chief Financial Officer | Company Secretary, Dimitra leads our finance and accounting functions as well as manages our human resources, facilities management and corporate IT services. Dimitra has 7 years of biotech experience in the management of clinical trial, clinical manufacturing and R&D forecasts/budgets as well as corporate operations.
She was previously Company Secretary of Immune System Therapeutics Ltd from 2011 to 2014. She has extensive experience in financial and managerial accounting, risk management and compliance gained in various senior financial roles with Cicada Innovations, CFO Plus, Apostle Financial Management, Absolute Capital Group, Australian Capital Reserve.
Halley has over 20 years experience in all areas of Project Co-ordination and Management within the Pharmaceutical Industry. Halley has worked within Large Pharma, CRO and Biotech across all areas of Clinical Research Management, including Global and Local Trial Management, Monitoring, Training, QC, Manufacturing, Regulatory and Preclinical. Halley was a member of the Immune System Therapeutics team from 2013 -14.
Halley holds a post-graduate Diploma in Drug Development (Medical Science) from the University of New South Wales. In 2008 she received the PharmaTimes International Clinical Researcher of the Year Award.